Global Cardiovascular Device Markets 2007-2012

Table of Contents

CHAPTER 1 INTRODUCTION

• 1.1 Aims of the report
• 1.2 Scope of the report
  • 1.2.1 Products included
  • 1.2.2 Markets included
  • 1.2.3 Years covered
  • 1.2.4 Methodology
  • 1.2.5 Forecasting
• 1.3 Conditions influencing the cardiovascular market
• 1.4 Lifestyle issues
• 1.5 Emerging markets
• 1.6 Regulation and reimbursement issues
• 1.7 Safety issues
• 1.8 Emergence of devices vs drugs
• 1.9 Cardiovascular device manufacturers
• 1.10 Technology trends

CHAPTER 2 MARKET OVERVIEW

• 2.1.1 Drivers and limiters

CHAPTER 3 CARDIAC RHYTHM MANAGEMENT

• 3.1 Cardiac rhythm background
• 3.2 Arrhythmias
  • 3.2.1 Types of arrhythmia
    • 3.2.1.1 Bradycardia
    • 3.2.1.2 Tachycardia
    • 3.2.1.3 Ventricular fibrillation
    • 3.2.1.4 Atrial fibrillation
    • 3.2.1.5 Tachyarrhythmias
    • 3.2.1.6 Bradytachycardia
    • 3.2.1.7 Heart block
    • 3.2.1.8 Premature ventricular contractions
• 3.3 Diagnosis of arrhythmias
• 3.4 Drug therapy
• 3.5 Pacemakers
  • 3.5.1 Single-chamber pacemakers
  • 3.5.2 Dual-chamber pacemakers
  • 3.5.3 Rate responsive pacemakers
  • 3.5.4 Cardiac resynchronisation therapy pacemaker
  • 3.5.5 Programming
  • 3.5.6 New clinical applications of pacemakers
  • 3.5.7 Companies and products
    • 3.5.7.1 Biotronik
    • 3.5.7.2 Boston Scientific
    • 3.5.7.3 Medtronic
    • 3.5.7.4 Sorin Group
    • 3.5.7.5 St Jude Medical
  • 3.5.8 Factors driving growth
  • 3.5.9 Market data
• 3.6 Implantable cardioverter defibrillators
  • 3.6.1 Effectiveness and clinical studies
  • 3.6.2 New clinical applications
  • 3.6.3 Companies and products
    • 3.6.3.1 Biotronik
    • 3.6.3.2 Boston Scientific
    • 3.6.3.3 Medtronic
    • 3.6.3.4 Sorin Group
    • 3.6.3.5 St Jude Medical
  • 3.6.4 Factors driving growth
  • 3.6.5 Market data
• 3.7 Automatic external defibrillators
  • 3.7.1 Effectiveness and clinical studies
  • 3.7.2 Companies and products
    • 3.7.2.1 Cardiac Science
    • 3.7.2.2 GE Healthcare
    • 3.7.2.3 Medtronic
    • 3.7.2.4 Philips Medical
    • 3.7.2.5 Schiller
    • 3.7.2.6 Zoll
  • 3.7.3 Market data
• 3.8 Pacemaker and defibrillator programmers
  • 3.8.1 Companies and products
    • 3.8.1.1 Biotronik
    • 3.8.1.2 Boston Scientific
    • 3.8.1.3 Medtronic
    • 3.8.1.4 St Jude Medical
    • 3.8.1.5 Sorin
  • 3.8.2 Market dynamics
• 3.9 Cardiac ablation devices
  • 3.9.1 Companies and products
    • 3.9.1.1 Boston Scientific
    • 3.9.1.2 CryoCath Technologies
    • 3.9.1.3 CryoCor
    • 3.9.1.4 Medtronic
    • 3.9.1.5 St Jude Medical
    • 3.9.1.6 Factors driving growth
  • 3.9.2 Market data

CHAPTER 4 CORONARY ARTERY DISEASE

• 4.1 Myocardial infarction
• 4.2 Acute myocardial infarction
• 4.3 Post-myocardial infarction
  • 4.3.1 First line therapies
    • 4.3.1.1 Beta-blockers
    • 4.3.1.2 ACE Inhibitors
    • 4.3.1.3 Aspirin
    • 4.3.1.4 Thrombolytic therapy
• 4.4 Diagnosis
  • 4.4.1 Cardiac markers
  • 4.4.2 Intravascular ultrasound
  • 4.4.3 Magnetic resonance imaging
  • 4.4.4 Computed tomography imaging
  • 4.4.5 Catheters
• 4.5 Surgery
  • 4.5.1 Coronary artery bypass graft surgery
  • 4.5.2 Anastomosis devices
  • 4.5.3 Robotic surgery
  • 4.5.4 Beating heart surgery devices
  • 4.5.5 Factors driving growth
  • 4.5.6 Market data
• 4.6 Angioplasty devices
  • 4.6.1 Factors driving growth
  • 4.6.2 Market
• 4.7 Stents
  • 4.7.1 Stent types
  • 4.7.2 Stent delivery
  • 4.7.3 Companies and products
  • 4.7.4 Factors driving growth
  • 4.7.5 Market data
• 4.8 Embolic protection systems
  • 4.8.1 Factors driving growth
  • 4.8.2 Market data

CHAPTER 5 HEART VALVE DISORDERS

• 5.1 Introduction
• 5.2 Valve repair annuloplasty devices
  • 5.2.1 Products
• 5.3 Mechanical valves
• 5.4 Tissue valves
  • 5.4.1 Human tissue valves
  • 5.4.2 Animal tissue valves
• 5.5 PFO devices and devices for closing other types of holes in the heart
  • 5.5.1 Patent foramen ovale
  • 5.5.2 Patent ductus arteriosus
  • 5.5.3 Ventricular septal defects
• 5.6 Factors driving growth
• 5.7 Market data

CHAPTER 6 END-STAGE HEART FAILURE

• 6.1 Available therapies
  • 6.1.1 Angiotensin receptor blockers (ARBs)
  • 6.1.2 Beta-blockers
  • 6.1.3 Digoxin
  • 6.1.4 Diuretics
  • 6.1.5 Aldosterone antagonists
  • 6.1.6 Left ventricular reduction surgery
  • 6.1.7 Intra-aortic balloon pumps
  • 6.1.8 Ventricular reshaping devices
  • 6.1.9 Ventricular assist devices
  • 6.1.10 Artificial hearts
• 6.2 Companies and products
  • 6.2.1 Abiomed
  • 6.2.2 Arrow International
  • 6.2.3 Berlin Heart
  • 6.2.4 CardiacAssist
  • 6.2.5 MicroMed Technology
  • 6.2.6 Jarvik Heart
  • 6.2.7 MEDOS Medizintechnik AG
  • 6.2.8 SynCardiac Systems
  • 6.2.9 Thoratec
  • 6.2.10 Ventracor
  • 6.2.11 WorldHeart
• 6.3 Factors driving growth
• 6.4 Market data

CHAPTER 7 MARKET ANALYSIS BY COUNTRY

• 7.1 The US
  • 7.1.1 Customer profile
  • 7.1.2 Regulations
  • 7.1.3 Reimbursement
  • 7.1.4 CRM device market
  • 7.1.5 Coronary artery disease device market
  • 7.1.6 Valve disorders market
  • 7.1.7 Congestive heart failure device market
• 7.2 Japan
  • 7.2.1 Customer profile
  • 7.2.2 Regulations
  • 7.2.3 Reimbursement
    • 7.2.3.1 Type A
    • 7.2.3.2 Type B
    • 7.2.3.3 Type C
    • 7.2.3.4 Type F
  • 7.2.4 CRM device market
  • 7.2.5 Coronary artery disease device market
  • 7.2.6 Valve disorders market
  • 7.2.7 Congestive heart failure device market
• 7.3 Germany
  • 7.3.1 Customer profile
  • 7.3.2 Regulations
  • 7.3.3 Reimbursement
  • 7.3.4 CRM device market
  • 7.3.5 Coronary artery disease device market
  • 7.3.6 Valve disorders market
  • 7.3.7 Congestive heart failure device market
• 7.4 France
  • 7.4.1 Customer profile
  • 7.4.2 Regulations
  • 7.4.3 Reimbursement
  • 7.4.4 CRM device market
  • 7.4.5 Coronary artery disease device market
  • 7.4.6 Valve disorders market
  • 7.4.7 Congestive heart failure device market
• 7.5 The UK
  • 7.5.1 Customer profile
  • 7.5.2 Regulations
  • 7.5.3 Reimbursement
  • 7.5.4 CRM device market
  • 7.5.5 Coronary artery disease device market
  • 7.5.6 Valve disorders market
  • 7.5.7 Congestive heart failure device market
• 7.6 Italy
  • 7.6.1 Customer profile
  • 7.6.2 Regulations
  • 7.6.3 Reimbursement
  • 7.6.4 CRM device market
  • 7.6.5 Coronary artery disease device market
  • 7.6.6 Valve disorders market
  • 7.6.7 Congestive heart failure device market
• 7.7 Spain
  • 7.7.1 Customer profile
  • 7.7.2 Regulations
  • 7.7.3 Reimbursement
  • 7.7.4 CRM device market
  • 7.7.5 Coronary artery disease device market
  • 7.7.6 Valve disorders market
  • 7.7.7 Congestive heart failure device market
• 7.8 China
  • 7.8.1 Customer profile
  • 7.8.2 Regulations
  • 7.8.3 Reimbursement
  • 7.8.4 CRM device market
  • 7.8.5 Coronary artery disease device market
  • 7.8.6 Valve disorders market
  • 7.8.7 Congestive heart failure device market
• 7.9 India
  • 7.9.1 Customer profile
  • 7.9.2 Regulations
  • 7.9.3 Reimbursement
  • 7.9.4 CRM device market
  • 7.9.5 Coronary artery disease device market
  • 7.9.6 Valve disorders market
  • 7.9.7 Congestive heart failure device market
• 7.10 The rest of the world
  • 7.10.1 South America
    • 7.10.1.1 Customer profile
    • 7.10.1.2 Argentina
    • 7.10.1.3 Brazil
    • 7.10.1.4 Chile
    • 7.10.1.5 Columbia
    • 7.10.1.6 Mexico
    • 7.10.1.7 Peru
    • 7.10.1.8 Venezuela
  • 7.10.2 South East Asia
    • 7.10.2.1 Customer profile
    • 7.10.2.2 Indonesia
    • 7.10.2.3 Malaysia
    • 7.10.2.4 Philippines
    • 7.10.2.5 Singapore
    • 7.10.2.6 South Korea
    • 7.10.2.7 Taiwan
    • 7.10.2.8 Thailand
    • 7.10.2.9 Vietnam
  • 7.10.3 Australia
    • 7.10.3.1 Customer profile
    • 7.10.3.2 Regulations
    • 7.10.3.3 Reimbursement
    • 7.10.3.4 The market

CHAPTER 8 COMPANY PROFILES

LIST OF TABLES

• Table 1.1 Prevalence of hypertension in major medical device markets 2004-2011
• Table 2.1 US Versus non-US sales of key industry players in 2006
• Table 2.2 Cardiac rhythm management
• Table 2.3 Interventional cardiology
• Table 2.4 Stents
• Table 2.5 Angioplasty balloons and catheters
• Table 2.6 Vascular closure devices
• Table 3.1 Major suppliers of pacemakers and their brands
• Table 3.2 Pacemaker prices in 2005 ($)
• Table 3.3 European pacing centres per million population
• Table 3.4 European countries with the highest rates of implanted pacemakers per million population, in 2005
• Table 3.5 European countries with the lowest rates of implanted pacemakers per million population in 2005
• Table 3.6 Major suppliers of ICDs and their brands
• Table 4.1 MRI and CT installed base per million of population
• Table 4.2 Trends in average costs by hospital procedure and volume 1988-2000
• Table 6.1 ACC/AHA Classification of chronic heart failure
• Table 6.2 New York Heart Association Heart Failure Symptom Classification System
• Table 6.3 Principal indications for intra-aortic balloon pump
• Table 6.4 VAD by manufacturer 2007
• Table 7.1 Cardiovascular operations (thousands) in the US in 2004
• Table 7.2 Estimated direct costs ($ billion) of cardiovascular disease and Stroke, U.S. 2004
• Table 7.3 510(k) v PMA approval process in the US
• Table 7.4 Cardiovascular HRGs in the UK

LIST OF FIGURES

• Figure 1.1 Deaths by cause 2005
• Figure 2.1 Medical device market by sector 2007
• Figure 2.2 Segmentation of cardiovascular market 2007
• Figure 2.3 Segmentation of cardiovascular market 2011
• Figure 3.1 Value of the world pacemaker market ($ millions)
• Figure 3.2 Company share of the world pacemaker market 2007
• Figure 3.3 Value of the world ICD market ($ millions)
• Figure 3.4 Company share of the world ICD market 2007
• Figure 3.5 Value of the world AED market ($ millions)
• Figure 3.6 Company share of the world AED market 2007
• Figure 3.7 Value of the world cardiac ablation market ($ millions)
• Figure 3.8 Company share of the world cardiac ablation market 2007
• Figure 4.1 Value of the world cardiac surgical equipment & tools market ($ millions)
• Figure 4.2 Value of the world bypass & disposables market ($ millions)
• Figure 4.3 Value of the world minimally invasive coronary artery bypass market ($ millions)
• Figure 4.4 Value of the world angioplasty and balloon catheter market ($ millions)
• Figure 4.5 Value of the world bare metal stent market ($ millions)
• Figure 4.6 Value of the world drug eluting stent market ($ millions)
• Figure 4.7 Value of the world embolic protection market ($ millions)
• Figure 5.1 Value of the world tissue heart valve market $ millions
• Figure 5.2 Company share of the world tissue heart valve market 2007
• Figure 5.3 Value of the world mechanical heart valve market $ millions
• Figure 5.4 Company share of the world mechanical heart valve market 2007
• Figure 5.5 Value of the world heart valve repair market $ millions
• Figure 5.6 Company share of the world heart valve repair market 2007
• Figure 6.1 Value of the world VAD market $ millions
• Figure 6.2 Value of the world intra aortic balloon pump market $millions